DNAtriX Secures $20,000,000 Series B Funding Round

  • Feed Type
  • Date
    10/14/2014
  • Company Name
    DNAtriX
  • Mailing Address
    One Greenway Plaza Houston, TX 77046 USA
  • Company Description
    DNAtriX, Inc. is a Texas-based biotechnology company focused on the development of an oncoloytic virus platform initially for the treatment of malignant glioma. DNAtriX’s lead product, delta24RGD, is a next-generation adenovirus invented by company founder Dr. Juan Fueyo and Dr. Frank McCormick.
  • Website
    http://www.dnatrix.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $20,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Securing this funding is a significant milestone that will enable us to advance our lead oncolytic virus product, DNX-2401, into late stage clinical trials for glioblastoma.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy